
Lorena Maestre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1793424/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. European Journal of Immunology, 2005, 35, 1681-1691.	2.9	528
2	Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica, 2007, 92, 1059-1066.	3.5	142
3	FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia, 2005, 19, 2247-2253.	7.2	131
4	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625.	5.9	130
5	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica, 2010, 95, 1342-1349.	3.5	128
6	Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia, 2009, 23, 1847-1857.	7.2	87
7	Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clinical Cancer Research, 2017, 23, 6315-6324.	7.0	73
8	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica, 2006, 91, 467-74.	3.5	70
9	Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood, 2008, 111, 351-358.	1.4	69
10	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. American Journal of Human Genetics, 2019, 104, 651-664.	6.2	51
11	Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers. Nature Communications, 2016, 7, 13418.	12.8	46
12	The European antibody network's practical guide to finding and validating suitable antibodies for research. MAbs, 2016, 8, 27-36.	5.2	46
13	Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma. American Journal of Pathology, 2010, 177, 930-942.	3.8	41
14	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0125203.	2.5	30
15	Simultaneous detection of the immunophenotypic markers and genetic aberrations on routinely processed paraffin sections of lymphoma samples by means of the FICTION technique. Leukemia, 2004, 18, 348-353.	7.2	28
16	Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica, 2009, 94, 419-422.	3.5	27
17	ChiTaRS 2.1—an improved database of the chimeric transcripts and RNA-seq data with novel sense–antisense chimeric RNA transcripts. Nucleic Acids Research, 2015, 43, D68-D75.	14.5	26
18	Genetic Immunization: A New Monoclonal Antibody for the Detection of BCL-6 Protein in Paraffin Sections. Journal of Histochemistry and Cytochemistry, 2006, 54, 31-38.	2.5	12

LORENA MAESTRE

#	Article	IF	CITATIONS
19	High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. PLoS ONE, 2020, 15, e0229743.	2.5	10
20	BCL7A protein expression in normal and malignant lymphoid tissues. British Journal of Haematology, 2013, 160, 106-109.	2.5	9
21	Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. Immunology Letters, 2011, 134, 150-156.	2.5	8
22	Generation of a New Monoclonal Antibody Against MALT1 by Genetic Immunization. Hybridoma, 2007, 26, 86-91.	0.4	3
23	CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. Cancers, 2022, 14, 2154.	3.7	1
24	FOXP3 Expression in B and T Cell Lymphomas Blood, 2005, 106, 4503-4503.	1.4	0